加拿大三级转诊中心前瞻性实施2015年ATA指南及改良ATA复发风险分层系统治疗分化型甲状腺癌
本研究在加拿大卡尔加里前瞻性纳入2017年4月至2021年12月治疗的612例分化型甲状腺癌(DTC)患者,按改良ATA复发风险(RR)分层和AJCC第8版分期指导手术及放射性碘(RAI)治疗,479例有2年随访数据。2年治疗反应(RTT)极佳率在肺叶切除组为89%、全甲状腺切除(TTX)组为84%、TTX+RAI组为53%;低、中、高RR组的极佳RTT率分别为85%、64%、38%。作者认为2015年ATA RR分层系统有助于预测DTC治疗后2年疾病状态,指南及改良分层推荐可能减少过度治疗。
要点
- 低RR组85%(216例)达极佳RTT,高RR组仅38%(37例)达极佳RTT。
- 肺叶切除组极佳RTT率89%(66例),TTX组84%(149例),TTX+RAI组53%(121例)。
- 高RR组结构不完全RTT达33%(32例),低RR组仅1例。
核心结论
- 2015年ATA RR分层系统有助于预测DTC患者治疗后2年疾病状态。
- 2015年ATA指南及改良ATA RR分层治疗推荐可能通过将肺叶切除作为低危甲状腺癌的确定性治疗选择、并对中高危患者选择性使用RAI来减少甲状腺癌过度治疗。
研究设计与样本
- 前瞻性分析2017年4月至2021年12月在加拿大阿尔伯塔省卡尔加里治疗的612例DTC患者。
- 每例患者前瞻性分配改良ATA RR分层及AJCC第8版分期,初始风险分层和2015年ATA指南指导手术管理及RAI和其他辅助治疗的指征与剂量。
- 479例患者有2年随访数据并纳入研究。
主要发现
- 479例中低RR 253例(53%)、中RR 129例(27%)、高RR 97例(20%)。
- 227例(47%)行全甲状腺切除(TTX)+RAI,178例(37%)仅行TTX,74例(16%)行肺叶切除。
- 2年RTT极佳率:肺叶切除组89%(66例),仅TTX组84%(149例),TTX+RAI组53%(121例)。
- 低RR组253例中极佳RTT 85%(216例)、不确定RTT 13%(32例)、生化不完全RTT 2%(4例)、结构不完全RTT 1例。
- 中RR组RTT:极佳64%(83例)、不确定23%(30例)、生化不完全6%(7例)、结构不完全7%(9例)。
关键数值与推荐
- 改良ATA复发风险(RR)分层:低RR 253例(53%)、中RR 129例(27%)、高RR 97例(20%)。
- 2年RTT极佳率:低RR组85%(216例)vs 中RR组64%(83例)vs 高RR组38%(37例)。
- 2年RTT结构不完全率:低RR组1例 vs 中RR组7%(9例)vs 高RR组33%(32例)。
临床怎么用
- 初始风险分层和2015年ATA指南指导手术管理及RAI和其他辅助治疗的指征与剂量。
- 作者认为2015年ATA指南及改良ATA RR分层治疗推荐可能减少甲状腺癌过度治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To present clinical outcomes of the prospective implementation of the 2015 American Thyroid Association (ATA) guidelines for the management of thyroid nodules and differentiated thyroid cancer (DTC) using the modified ATA recurrence risk (RR) stratification system. Methods: We prospectively analyzed 612 patients with DTC treated between April 2017 and December 2021 in Calgary, Alberta. Each patient was prospectively assigned a modified ATA RR and American Joint Committee Cancer 8th edition stage. Initial risk stratification and consideration of the 2015 ATA guidelines guided surgical management as well as the indication for and dose of radioiodine (RAI) and other adjuvant therapies. Patients were assessed for their response to treatment (RTT) at 2-years postoperatively. Results: There were 479 patients who had 2-year follow-up data and were included in the study. Of these patients, there were 253 (53%) low-, 129 (27%) intermediate-, and 97 (20%) high-RR patients. Of these, 227 patients (47%) underwent total thyroidectomy (TTX) plus RAI, 178 (37%) underwent TTX only, and 74 (16%) underwent lobectomy. The RTT at 2 years was excellent for 89% (66) of patients with lobectomy, 84% (149) for TTX only, and 53% (121) for TTX plus RAI. Among 253 patients who were deemed low RR, 85% (216) had excellent RTT, 13% (32) indeterminate RTT, 2% (4) biochemical incomplete RTT, and 1 patient had structural incomplete RTT. The intermediate RR group had the following RTT outcomes: 64% (83) excellent, 23% (30) indeterminate, 6% (7) biochemical incomplete, and 7% (9) structural incomplete. The high RR group had the worst RTT outcomes, with 38% (37) excellent, 19% (18) indeterminate, 10% (10) biochemical incomplete, and 33% (32) structural incomplete RTT. Conclusions: The 2015 ATA RR stratification system is useful for predicting disease status at 2-year post-treatment in patients with DTC. The 2015 ATA guidelines and modified ATA RR stratification treatment recommendations may reduce thyroid cancer overtreatment by including lobectomy as a definitive treatment option for low-risk thyroid cancers and selective use of RAI for intermediate and high-risk patients.
引用
- Wu J, Hu XY, Ghaznavi S, et al. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting. Thyroid. 2022. PMID: 36226405. doi:10.1089/thy.2022.0055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。